This will be one of the largest public issues by a domestic drug manufacturer after the ₹6,480-crore IPO of Gland Pharma in 2020. The qualified institutional buyers (QIB) category was subscribed 49 times, while the non-institutional investors or high net-worth individuals’ portion was subscribed 3.8 times. However, the retail investor’s portion was under-subscribed at 92%.
Sebi proposes tighter curbs on promotional claims by online bond platforms
Sebi is tightening the reins on advertising practices for online bond platforms, aiming to protect investors from hasty decisions. New rules mandate that promotional content